27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Argus’ Jacob Kilstein believes Zoetis Inc (NYSE: ZTS) has been benefiting from a “lack of generic competition in the animal drug space.”
Kilstein maintains a Buy rating on the company, while raising the price target from $54 to $58.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Benefiting From Animal Drug Space
The analyst mentioned that the company also continues to benefit from its shorter R&D and launch cycle, given that animal products can be tested more quickly than human drugs.
“The company also benefits from broad diversification across product categories and customers, with a wide range of products for cattle, swine, poultry, and companion animals. This diversification has enabled Zoetis to offset weak sales in a particular segment with stronger sales in others,” Kilstein explained.
Q2 And Guidance
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Zoetis reported its Q2 results ahead of expectations, with 14 percent growth in operational earnings, driven by the companion animal business, U.S. cattle business, international expansion and new products.
“Management has raised its 2016 adjusted EPS guidance to $1.86–$1.93 from $1.83–$1.90, which assumes stronger sales growth and more moderate currency headwinds,” Kilstein stated.
Outlook
The analyst expects Zoetis’ growth to accelerate into 2017, as issues such as inventory stockpiling and currency losses are cycled through and the restructuring benefits begin to bear fruit.
“Its lead product, Apoquel, a dermatitis treatment for dogs, generated $110 million in sales in 2015 and management projects long-term peak sales of more than $300 million,” according to the Argus report.
The analyst also noted Zoetis has a robust new product pipeline, and CEO Juan Alaix had noted during the Q2 call that the initial sales for the recently launched Simparica were strong.
The EPS estimates for 2016 and 2017 have been raised.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.